Merck Takes A Shot At A June Approval For HPV Vaccine Gardasil
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm requests a priority review for the human papillomavirus vaccine’s BLA, submitted Dec. 1.
You may also be interested in...
Gardasil User Fee Date Extended By A Week
Merck's BLA submission date for its human papillomavirus vaccine Gardasil has been delayed by an "initial cursory review" by FDA, the company said
Gardasil User Fee Date Extended By A Week
Merck's BLA submission date for its human papillomavirus vaccine Gardasil has been delayed by an "initial cursory review" by FDA, the company said
Merck Sales Restructuring Sacrifices Physician Detailing To Payer Marketing
Merck's restructuring program is shifting selling and marketing resources away from physician detailing towards payer and patient promotion, CEO Richard Clark indicated during the firm's annual business review in Whitehouse Station, N.J